ClinicalTrialsFinder
RecruitingPhase 1NCT06944444

A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors

A Phase I Clinical Study of the Safety, Pharmacokinetics, and Antitumor Activity of SSS59 in Patients With Advanced Malignant Tumors

Sponsor

Shenyang Sunshine Pharmaceutical Co., LTD.

Enrollment

154 participants

Start Date

Apr 27, 2025

Study Type

INTERVENTIONAL

Conditions

Malignant Tumors

Summary

This study was an open-label phase I study to evaluate the safety, pharmacokinetics, and antitumor activity of SSS59 as a single agent in patients with advanced malignancies.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called SSS59 for people with malignant tumors. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSSS59

A humanized antibody targeting MUC17

Locations(1)

Shanghai First People's Hospital

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06944444

Related Trials

Correlation Analysis of Gene Characteristics of Malignant Tumors With Prognosis

NCT076226671 location

A Study of LM-350 in Subjects With Advanced Solid Tumours

NCT071122224 locations

Clinical Application of 68Ga-FL-031 PET in the Diagnosis and Staging of Malignant Tumors

NCT073018011 location

Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies

NCT070042441 location

Study of LM-299 in Subjects Advanced Malignant Tumors

NCT066505666 locations